Original Title: Fantom sirolimus-eluting BRS – FANTOM II Trial.
Presenter: Alexandre Abizaid
This new sirolimus eluting bioresorbable scaffold is the only one which can be directly visualized using conventional angiography. It is able to be expanded to its nominal size in one smooth and continuous inflation step, minimizing artery occlusion time.
This was a safety and efficacy study preformed in 240 patients with target vessel reference diameters between 2.5 and 3.5 mm and ˂20 mm lesions. The population was divided in 2 cohorts and angiographic follow up was at 6 months (117 patients, cohort A) and at 9 months (123 patients, cohort B). Imaging testing including IVUS and OCT was performed at 24 months (cohort A) and 48 months (cohort B). Cohort A outcomes presented 1.7% events rate at 6 months and no cardiac deaths.
Conclusion
The sirolimus eluting bioresorbable scaffold with new interesting features showed really good outcomes at 6 months in terms of safety and efficacy.
fantom
